Success Story: Advancing the Next Generation of Tumor-Focused Treatment Platforms, NIW Approval Secured for a Chinese Senior Research Associate
Client’s Testimonial:
“I had an excellent experience working with Chen Immigration Law Associates (WeGreened) on my employment-based immigration petitions. From start to finish, the team was highly professional, knowledgeable, detail-oriented, and exceptionally well organized.
I am especially grateful to my attorneys and the entire team for their outstanding expertise, accurate judgment, and clear strategic guidance. Based on their advice, I pursued both NIW and EB1A petitions, which turned out to be an excellent decision. Thanks to their careful planning and strong case preparation, my I-140 was approved in a timely manner, allowing me to confidently move forward with my H-1B renewal planning. Throughout the process, the team responded promptly to my questions, explained each step clearly, and paid close attention to every detail of my case. Their professionalism and transparency gave me great confidence during an otherwise complex and stressful process.
I truly appreciate their dedication and high standards of work. I am happy to have my success story shared and sincerely hope it will help others considering employment-based immigration options. I would highly recommend Chen Immigration / WeGreened to anyone pursuing EB-1, NIW, or other employment-based immigration petitions.”
On January 14th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Senior Research Associate in the field of Pharmacology (Approval Notice).
General Field: Pharmacology
Position at the Time of Case Filing: Senior Research Associate
Country of Origin: China
State of Residence at the Time of Filing: Texas
Approval Notice Date: January 14th, 2026
Processing Time: 9 months, 26 days (Premium Processing Requested)
Case Summary:
One independent expert summarized the value of this work in plain terms: “[Client] supports innovation in oncology and drives progress in related areas of cancer biology and drug development by advancing pharmacological research in the United States.”
Targeted cancer therapy often succeeds or fails on a practical tradeoff. The drug must be potent enough to eliminate tumor cells, but precise enough to avoid collateral damage to healthy tissue. This NIW case centered on a pharmacology researcher whose work addresses that tradeoff directly by improving drug-conjugate therapies. The scientific goal is straightforward: make the “delivery vehicle” more selective, so the therapeutic payload reaches tumor cells more reliably and causes fewer off-target effects.
North America Immigration Law Group (NAILG) structured the case around two adjudicator-friendly themes: (1) why this research direction matters at a systems level for cancer care, and (2) why the record showed the client can keep pushing it forward in the United States. The filing emphasized that these targeted drug-conjugate strategies reflect a more modern treatment logic, engineering therapeutic delivery to concentrate in tumor cells while limiting exposure to healthy tissue, improving both effectiveness and tolerability in settings where current options remain limited or overly toxic.
A distinguishing feature of this record was external validation that the work aligns with national health priorities. The case highlighted competitive support from the National Institutes of Health (NIH) and the Cancer Prevention and Research Institute of Texas (CPRIT), reinforcing that the underlying research direction has been evaluated and backed by major decision-makers funding cancer-focused innovation.
The “well-positioned” showing was built on execution. The client holds a Ph.D. in Pharmacology and has an established record of research output and influence: 25 peer-reviewed journal articles (6 of them first-authored), 1 abstract, 2 preprints, and 977 citations. Importantly, those citations were presented as evidence of independent reliance, showing that other scientists have used the client’s findings to inform ongoing work across multiple disease and safety contexts, including treatment strategy development in oncology and refinement of therapeutic approaches where efficacy must be balanced with risk.
USCIS approved the NIW petition, recognizing a record that linked sophisticated pharmacology to a clear public-health need: safer, more specific cancer therapies that improve outcomes while reducing harmful side effects. NAILG appreciated the opportunity to present this work in a clear, privacy-conscious way and to secure a result that supports continued progress in targeted oncology drug development in the United States.